Skip to content

Central Blood Pressure Over 24 Hours (ABPM) and Left Ventricular Mass

Central Blood Pressure Over 24 Hours (ABPM) and Left Ventricular Mas

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01278732
Enrollment
350
Registered
2011-01-19
Start date
2011-01-31
Completion date
2015-03-31
Last updated
2015-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Suspected Arterial Hypertension

Keywords

arterial hypertension

Brief summary

The investigators aim to investigate whether central systolic blood pressure, as measured during regular 24 hour ambulatory blood pressure monitoring (ABPM), is a better predictor of left ventricular mass than peripheral systolic blood pressure during ABPM.

Detailed description

It seems obvious that central blood pressures are pathophysiologically more relevant than peripheral blood pressures for the pathogenesis of cardiovascular disease: it is central systolic pressure (cSBP) against the heart ejects (afterload), and it is central pulse pressure (cPP) that distends the large elastic arteries. Indeed, cSBP and cPP have been associated more closely with left ventricular hypertrophy and carotid atherosclerosis as markers of hypertensive end-organ damage than brachial pressures in various populations. However, in these studies office blood pressure measurements have been used. As ABPM measurements per se show a closer association with hypertensive end-organ damage than office measurements, and as the investigators have recently developed and validated a novel algorithm (ARCSolver) to calculate central blood pressures from peripheral waveforms, the investigators speculate that cSBP measured during ABPM may be the best predictor of left ventricular mass.

Interventions

no intervention is performed

Sponsors

Austrian Society of Hypertension
CollaboratorUNKNOWN
European Regional Development Fund
CollaboratorOTHER
I.E.M. (Stolberg, Germany)
CollaboratorUNKNOWN
Klinikum Wels-Grieskirchen
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

\> 18 years of age, * no intake of antihypertensive medications * should have an indication for ABPM (suspected arterial hypertension)

Exclusion criteria

* no written informed consent * left ventricular hypertrophy due to other reasons than hypertension (hypertrophic cardiomyopathy, infiltrative cardiomyopathy, valvular heart disease, congenital heart disease) * inability to provide adequate echocardiographic readings * segmental contraction abnormalities of the left ventricle * contraindications for ABPM (lymphedema both arms) * other rhythm than stable sinus rhythm * unstable clinical condition, including recent severe infections

Design outcomes

Primary

MeasureTime frame
Left ventricular mass (m-mode echocardiography)measured within 4 weeks from ABPM

Secondary

MeasureTime frame
urine albumine / creatinine ratiomeasured within 2 weeks from ABPM but before antihypertensive treatment is started

Countries

Austria, Germany, Greece, Italy, Spain, Switzerland, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026